Literature DB >> 26130522

In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5.

Sabine Pellett1, William H Tepp2, Regina C M Whitemarsh2, Marite Bradshaw2, Eric A Johnson2.   

Abstract

To date, over 40 subtypes of botulinum neurotoxins (BoNTs) have been identified. BoNTs are classified into 7 serotypes distinguished primarily by their antigenic properties, but also characterized by their unique SNARE targets and cleavage sites, host specificity, and duration of action. Sequencing efforts in the last decade have identified several subtypes within the serotypes. Subtypes are currently defined as distinct based solely on amino acid sequence comparison, with a similarity cut-off of 2.5% difference. Ten subtypes have been identified for BoNT/A, which is the serotype associated with the most severe human botulism and also the most commonly used serotype for clinical purposes. Analyses of several of these subtypes have revealed distinct characteristics, ranging from differences in cell entry and enzyme kinetics to differences in potency in mice and cell-model specific potency. A long-term activity study in cultured primary neurons has indicated that BoNT/A1, 2, 4, and 5 have a similar duration of action, whereas BoNT/A3 has a significantly shorter duration of action. This report describes an in vivo mouse study, showing that after local injection BoNT/A2 resulted in faster onset of local paralysis than BoNT/A1, 3, 4, and 5, whereas BoNT/A3 resulted in significantly faster recovery of motor-neuron deficiency.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BoNT/A; Botulinum neurotoxin; Duration of action; Rotarod; Subtypes

Mesh:

Substances:

Year:  2015        PMID: 26130522      PMCID: PMC4658214          DOI: 10.1016/j.toxicon.2015.06.021

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  41 in total

Review 1.  Clinical applications of botulinum toxin.

Authors:  Dirk Dressler
Journal:  Curr Opin Microbiol       Date:  2012-07-05       Impact factor: 7.934

Review 2.  Botulinum neurotoxin: a marvel of protein design.

Authors:  Mauricio Montal
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

Review 3.  The typing of botulinal neurotoxins.

Authors:  D F Giménez; J A Giménez
Journal:  Int J Food Microbiol       Date:  1995-09       Impact factor: 5.277

4.  Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity.

Authors:  Andreas Rummel
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

5.  Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes.

Authors:  Karen K Hill; Theresa J Smith
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 6.  Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).

Authors:  Francisco Cruz; Victor Nitti
Journal:  Neurourol Urodyn       Date:  2014-07       Impact factor: 2.696

7.  Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5.

Authors:  Dongxia Wang; Joan Krilich; Sabine Pellett; Jakub Baudys; William H Tepp; John R Barr; Eric A Johnson; Suzanne R Kalb
Journal:  Biochim Biophys Acta       Date:  2013-10-02

8.  Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.

Authors:  Regina C M Whitemarsh; William H Tepp; Marite Bradshaw; Guangyun Lin; Christina L Pier; Jacob M Scherf; Eric A Johnson; Sabine Pellett
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

9.  Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.

Authors:  Yasushi Torii; Naotoshi Kiyota; Nakaba Sugimoto; Yuichiro Mori; Yoshitaka Goto; Tetsuhiro Harakawa; Shinji Nakahira; Ryuji Kaji; Shunji Kozaki; Akihiro Ginnaga
Journal:  Toxicon       Date:  2010-10-26       Impact factor: 3.033

10.  Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins.

Authors:  Marco Pirazzini; Domenico Azarnia Tehran; Giulia Zanetti; Aram Megighian; Michele Scorzeto; Silvia Fillo; Clifford C Shone; Thomas Binz; Ornella Rossetto; Florigio Lista; Cesare Montecucco
Journal:  Cell Rep       Date:  2014-09-15       Impact factor: 9.423

View more
  34 in total

Review 1.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

2.  Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.

Authors:  Abby R Kroken; Faith C Blum; Madison Zuverink; Joseph T Barbieri
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

3.  Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").

Authors:  Sabine Pellett; William H Tepp; Guangyun Lin; Eric A Johnson
Journal:  Toxicon       Date:  2017-12-19       Impact factor: 3.033

4.  Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.

Authors:  Molly S Moritz; William H Tepp; Heather N'te Inzalaco; Eric A Johnson; Sabine Pellett
Journal:  Toxicon       Date:  2019-06-07       Impact factor: 3.033

5.  Botulinum neurotoxins A, B, C, E, and F preferentially enter cultured human motor neurons compared to other cultured human neuronal populations.

Authors:  Sabine Pellett; William H Tepp; Eric A Johnson
Journal:  FEBS Lett       Date:  2019-07-04       Impact factor: 4.124

6.  The Structure and Classification of Botulinum Toxins.

Authors:  Min Dong; Pål Stenmark
Journal:  Handb Exp Pharmacol       Date:  2021

7.  A Novel Running Wheel Mouse Model for Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.

Authors:  Arieh Schwartz; Alon Ben David; Mordechai Hotoveli; Eyal Dor; Eran Diamant; Arik Vivyorka; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

8.  Crystal structure of the catalytic domain of botulinum neurotoxin subtype A3.

Authors:  Oneda Leka; Yufan Wu; Xiaodan Li; Richard A Kammerer
Journal:  J Biol Chem       Date:  2021-04-20       Impact factor: 5.157

Review 9.  Current status and future directions of botulinum neurotoxins for targeting pain processing.

Authors:  Sabine Pellett; Tony L Yaksh; Roshni Ramachandran
Journal:  Toxins (Basel)       Date:  2015-11-04       Impact factor: 4.546

Review 10.  Impact of Clostridium botulinum genomic diversity on food safety.

Authors:  Michael W Peck; Arnoud Hm van Vliet
Journal:  Curr Opin Food Sci       Date:  2016-08       Impact factor: 6.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.